DNTH Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of -9284.09% compared to Dianthus Therapeutics, Inc.'s net margin of -116.82%. Dianthus Therapeutics, Inc.'s return on equity of -33.81% beat Agenus, Inc.'s return on equity of --.

Dianthus Therapeutics, Inc. has a consensus price target of $74.45, signalling upside risk potential of 34.74%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 269.26%. Given that Agenus, Inc. has higher upside potential than Dianthus Therapeutics, Inc., analysts believe Agenus, Inc. is more attractive than Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc. has a beta of 1.560, which suggesting that the stock is 55.95% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.567, suggesting its more volatile than the S&P 500 by 56.664%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.

Dianthus Therapeutics, Inc. quarterly revenues are $396K, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Dianthus Therapeutics, Inc.'s net income of -$36.8M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 648.29x versus 0.84x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Biogen, Inc. has a net margin of -9284.09% compared to Dianthus Therapeutics, Inc.'s net margin of -2.24%. Dianthus Therapeutics, Inc.'s return on equity of -33.81% beat Biogen, Inc.'s return on equity of 7.36%.

Dianthus Therapeutics, Inc. has a consensus price target of $74.45, signalling upside risk potential of 34.74%. On the other hand Biogen, Inc. has an analysts' consensus of $205.67 which suggests that it could grow by 9.37%. Given that Dianthus Therapeutics, Inc. has higher upside potential than Biogen, Inc., analysts believe Dianthus Therapeutics, Inc. is more attractive than Biogen, Inc..

Dianthus Therapeutics, Inc. has a beta of 1.560, which suggesting that the stock is 55.95% more volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.151, suggesting its less volatile than the S&P 500 by 84.865%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

Dianthus Therapeutics, Inc. quarterly revenues are $396K, which are smaller than Biogen, Inc. quarterly revenues of $2.2B. Dianthus Therapeutics, Inc.'s net income of -$36.8M is higher than Biogen, Inc.'s net income of -$48.9M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 21.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 648.29x versus 2.90x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cartesian Therapeutics, Inc. has a net margin of -9284.09% compared to Dianthus Therapeutics, Inc.'s net margin of -7942.92%. Dianthus Therapeutics, Inc.'s return on equity of -33.81% beat Cartesian Therapeutics, Inc.'s return on equity of --.

Dianthus Therapeutics, Inc. has a consensus price target of $74.45, signalling upside risk potential of 34.74%. On the other hand Cartesian Therapeutics, Inc. has an analysts' consensus of $35.57 which suggests that it could grow by 368.05%. Given that Cartesian Therapeutics, Inc. has higher upside potential than Dianthus Therapeutics, Inc., analysts believe Cartesian Therapeutics, Inc. is more attractive than Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc. has a beta of 1.560, which suggesting that the stock is 55.95% more volatile than S&P 500. In comparison Cartesian Therapeutics, Inc. has a beta of 0.568, suggesting its less volatile than the S&P 500 by 43.183%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cartesian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Cartesian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Dianthus Therapeutics, Inc. quarterly revenues are $396K, which are smaller than Cartesian Therapeutics, Inc. quarterly revenues of $452K. Dianthus Therapeutics, Inc.'s net income of -$36.8M is lower than Cartesian Therapeutics, Inc.'s net income of -$35.9M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Cartesian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 648.29x versus 84.79x for Cartesian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Royalty Pharma Plc has a net margin of -9284.09% compared to Dianthus Therapeutics, Inc.'s net margin of 57.24%. Dianthus Therapeutics, Inc.'s return on equity of -33.81% beat Royalty Pharma Plc's return on equity of 13.52%.

Dianthus Therapeutics, Inc. has a consensus price target of $74.45, signalling upside risk potential of 34.74%. On the other hand Royalty Pharma Plc has an analysts' consensus of $51.56 which suggests that it could grow by 8.61%. Given that Dianthus Therapeutics, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe Dianthus Therapeutics, Inc. is more attractive than Royalty Pharma Plc.

Dianthus Therapeutics, Inc. has a beta of 1.560, which suggesting that the stock is 55.95% more volatile than S&P 500. In comparison Royalty Pharma Plc has a beta of 0.403, suggesting its less volatile than the S&P 500 by 59.666%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Royalty Pharma Plc offers a yield of 1.89% to investors and pays a quarterly dividend of $0.24 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Royalty Pharma Plc pays out 49.4% of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dianthus Therapeutics, Inc. quarterly revenues are $396K, which are smaller than Royalty Pharma Plc quarterly revenues of $622M. Dianthus Therapeutics, Inc.'s net income of -$36.8M is lower than Royalty Pharma Plc's net income of $356M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Royalty Pharma Plc's PE ratio is 26.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 648.29x versus 10.62x for Royalty Pharma Plc. Usually stocks with elevated PS ratios are considered overvalued.